Replies to post #223857 on Biotech Values

[DewDiligence]

Something doesn't add up...

Inefficiencies in the valuations of small biotech companies can persist for quite a while. For instance, ENTA was trading at ~$45 as recently as Nov 2017—several months after Mavyret's approval by the FDA and CHMP (#msg-136356320).